{
  "abstract": "Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00702-026-03233-w.",
  "abstract_shown": true,
  "affiliations": [
    "1A Consulting, Dr Wach & Wach GbR, Weil am Rhein, Germany",
    "Zambon Biotech SA, Medical Affairs, Cadempino, Switzerland",
    "Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, SE1 1UL UK"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Achim Wach"
    },
    {
      "affs": [
        1
      ],
      "name": "Jaakko Kopra"
    },
    {
      "affs": [
        1
      ],
      "name": "Ivan Marjanovic"
    },
    {
      "affs": [
        1
      ],
      "name": "Mathias Knecht"
    },
    {
      "affs": [
        2
      ],
      "name": "Peter Jenner",
      "orcid": "0009-0006-0327-7584"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7mc27wqcyx9j0.bib",
  "cited_by": 0,
  "doi": "10.1007/s00702-026-03233-w",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13743624/",
  "id": "7mc27wqcyx9j0",
  "issns": [
    "0300-9564",
    "1435-1463"
  ],
  "landing_url": "https://doi.org/10.1007/s00702-026-03233-w",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7169864612",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s00702-026-03233-w.pdf",
  "pmcid": "PMC13743624",
  "pmid": "42479139",
  "published": "2026-07-21",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7mc27wqcyx9j0.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:21:18Z",
      "native_id": "PMC13743624",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s00702-026-03233-w"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Parkinson's Disease Mechanisms and Treatments",
      "subfield": "neurology"
    }
  ],
  "title": "Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers",
  "title_text": "Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers",
  "type": "peer-reviewed",
  "updated_at": "2026-11-11T12:21:18Z",
  "url": "https://research.draconitic.com/paper/7mc27wqcyx9j0",
  "venue": "Journal of Neural Transmission",
  "versions": []
}